Pharmacy Times

JUNE 24, 2022

The impact of the pandemic on the mental health of health care workers, including pharmacists and pharmacy staff, has been well documented.

Documentation 182

Documentation 182

European Pharmaceutical Review

JUNE 24, 2022

The Greek state has filed a lawsuit against Novartis , asking for € 214 million in compensation for non-pecuniary damages* the country may have suffered due to alleged illegal payments to government officials and healthcare providers. Commenting on the lawsuit , Greece’s Health Minister Thanos Plevris, stated that the country is seeking compensation for the damage it has suffered “from the actions that Novartis itself has admitted to in the USA that concerns payments to doctors.”.

139

139

pharmaphorum

JUNE 23, 2022

Eisai’s digital tool to allow self-assessment of cognitive performance – NouKNOW – will be used in a Japanese project aimed at improving the management of dementia. The smartphone app – which uses a cognition-checking algorithm developed by Australian digital health company Cogstate – will be deployed in Bunkyo City, Tokyo in a dementia monitoring programme.

137

137

PharmaVoice

JUNE 23, 2022

The company’s CEO explains how its Prix Galien award-winning app bridges patient care, treatment support and clinical research.

Patient Care 130

Patient Care 130

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Pharmacy Times

JUNE 22, 2022

Even if the financial resources were available, there aren’t enough human resources in pharmacy to provide high-touch engagement to the millions of patients who suffer from common chronic diseases.

181

181

IDStewardship

JUNE 21, 2022

In this article a pharmacist with significant experience in the area of finance identifies and discusses five common financial mistakes to avoid as a pharmacist. . Authored By: Timothy Ulbrich, PharmD. Co-Founder and CEO of Your Financial Pharmacist (YFP). Article posted 21 June 2022. While financial mistakes may seem inevitable, some do not have to be.

130

130

PharmExec

JUNE 20, 2022

The world’s largest cancer research meeting, the American Society of Clinical Oncology (ASCO) Annual Meeting, recently convened in person in Chicago after two years of being held virtually. Sara Baker and Kristine Austria Fan of Marina Maher Communications provide their takeaways from the meeting.

Communication 108

Communication 108

Pharmacy Times

JUNE 24, 2022

Amy Cadwallader, PhD, director of Regulatory and Public Policy Development at US Pharmacopeia (USP), discusses how medicine quality and the medicines supply chain can affect antimicrobial resistance (AMR).

172

172

Pharmaceutical Technology

JUNE 24, 2022

As regulatory agencies gear up for another round of Covid-19 vaccine deliberations centered on emerging variants, Moderna has released data on its booster’s efficacy against Omicron subvariants. In addition to providing protection against the Omicron BA.1 variant, on 22 June, Moderna said its booster also showed a “potent” antibody response against Omicron subvariants BA.4 and BA.5.

Vaccines 105

Vaccines Immunization FDA Hospitals 105

pharmaphorum

JUNE 21, 2022

Armed with new phase 3 data, AstraZeneca is preparing to file for regulatory approval of eplontersen, an antisense drug for one of the complications of the disease transthyretin amyloidosis (ATTR) it licensed from Ionis in a $3.6 billion deal last year. Eplontersen – previously known as IONIS-TTR-LRX – is designed to switch off the production of transthyretin (TTR), a protein which builds up in the disease to toxic levels causing heart problems (cardiomyopathy) and nerve damage (polyneuropathy).

FDA 111

FDA 111

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

European Pharmaceutical Review

JUNE 24, 2022

2022 is probably the biggest year in EU pharmaceutical law that I have seen in 30 years. It is an exciting year… but whether the changes will be a net positive or a net negative is yet to be seen” Maarten Meulenbelt, Partner, Sidley Austin LLP. 2022 is undeniably a critical year for change in the pharmaceutical industry: for the first time in several decades, the European Union (EU)’s pharmaceutical legislation is up for review.

Compounding 105

Compounding Packaging Dosage Communication 105

Pharmacy Times

JUNE 23, 2022

The Opioid and Naloxone program at North Dakota State University School of Pharmacy aims to make a difference.

171

171

Pharmaceutical Technology

JUNE 23, 2022

The European Commission (EC) has approved Novartis’ Tabrecta (capmatinib) as a monotherapy to treat advanced non-small cell lung cancer (NSCLC) in adults. The treatment is intended for patients with NSCLC harbouring alterations leading to mesenchymal-epithelial-transition factor gene (MET) exon 14 (METex14) skipping and for those who need systemic therapy after previous treatment with immunotherapy and/or platinum-based chemotherapy.

Chemotherapy 105

Chemotherapy 105

pharmaphorum

JUNE 22, 2022

Pfizer has harnessed the expertise of health data specialist Truveta to provide close monitoring of safety and other signals for its products, including COVID-19 vaccine Comirnaty, almost in real-time. Truveta’s platform is based on electronic medical record data – updated daily – for more than 50 million people in the US, harvesting anonymised patient care information from tens of thousands of clinical care sites across 42 states.

Medical Records 105

Medical Records Patient Care Vaccines Insurance 105

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

PharmaVoice

JUNE 20, 2022

In the evolution of healthcare, data is the linchpin to making drug development more efficient.

97

97

Pharmacy Times

JUNE 23, 2022

Insurers are refusing to cover new, highly effective anti-obesity drugs, but some prescribers are getting around the issue.

Insurance 164

Insurance 164

Pharmaceutical Technology

JUNE 24, 2022

Novavax has obtained emergency use authorization (EUA) for its Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), from the Taiwan Food and Drug Administration for use in people of the age 18 years and above. The protein-based vaccine is engineered from the genetic sequence of the SARS-CoV-2 virus’ initial strain. Developed utilising Novavax’s recombinant nanoparticle technology to generate antigen obtained from the coronavirus spike (S) protein, the vaccine is also formulated with the company’s saponin-

Vaccines 105

Vaccines FDA 105

pharmaphorum

JUNE 24, 2022

Last year, AstraZeneca reported that a new drug to treat Wilson disease developed by its Alexion rare diseases unit had hit the mark in a phase 3 trial, setting it on course for regulatory filings. Now, the data has been revealed – and according to investigators could transform treatment. Wilson disease is a rare and progressive genetic condition in which the body’s process for removing excess copper is broken, allowing it to build to toxic levels and damage the liver, brain and other vita

100

100

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

European Pharmaceutical Review

JUNE 24, 2022

BioNTech has initiated construction of its first vaccine production facility in Africa. Located in Kigali, Rwanda, the mRNA manufacturing facility will be the first of three planned sites across the continent, with further factories to come in Senegal and South Africa. Together this network of factories will supply therapies and vaccines solely for people residing in member states of the African Union.

Vaccines 96

Vaccines 96

Pharmacy Times

JUNE 24, 2022

Breast cancer screening guidelines using mammography vary among guiding bodies, including the American Cancer Society and the American Academy of Family Physicians.

153

153

Outsourcing Pharma

JUNE 22, 2022

The company reports it has met the enrollment target for a trial of its sonic beam therapy, one step closer to submitting for FDA approval of the product.

FDA 95

FDA 95

pharmaphorum

JUNE 20, 2022

Pfizer has acquired an 8.1% stake in French vaccines developer Valneva at a cost of €90.5 million (around $95 million) and rejigged the terms of their alliance to develop a shot for Lyme disease. The deal gives Valneva a cash injection that it will be able to use to advance Lyme disease candidate VLA15 towards the market, but the revised licensing terms means that the French biotech will shoulder more of the financial cost of the development programme.

Vaccines 98

Vaccines 98

Fossil Remedies

JUNE 23, 2022

If you see the growth pattern of the Indian economy, then it has been tremendous. The country has done remarkably well and despite the setback after the pandemic, it is roaring high with full speed. All sector of the Indian economy has done good, but the pharma sector is doing exceptionally well. It is among the fastest-growing sectors in India. Since there is an opportunity to earn, every dynamic business owner wants to reap benefits from that.

91

91

Pharmacy Times

JUNE 24, 2022

Abemaciclib (Verzenio; Eli Lilly and Company) is an FDA-approved kinase inhibitor being investigated for new indications in individuals with hormone-sensitive prostate cancer and castration-resistant prostate cancer.

FDA 149

FDA 149

PharmExec

JUNE 20, 2022

Additions of Andrew Johnson and Bridget Seay strengthen epocrates’ evolution as a commercial organization with best-in-class market intelligence and products.

75

75

pharmaphorum

JUNE 21, 2022

While proponents argue waiving IP on COVID-19 vaccines would better enable low- and middle-income countries to inoculate their populations, the pharma industry has called the proposals “unnecessary and harmful to innovation”. Proposals to waive COVID-19 product patents have been described as “political posturing” and an “answer to a problem that does not exist”.

Vaccines 98

Vaccines 98

Pharma Manufacturing

JUNE 24, 2022

Pharma can do better than 50% compliance

73

73

Pharmacy Times

JUNE 24, 2022

This is the first RSV vaccination candidate to show clinically meaningful and statistically significant efficacy in adults aged 60 years and older.

Vaccines 139

Vaccines 139

Outsourcing Pharma

JUNE 21, 2022

If new restrictions are placed on the FDAâs Accelerated Approval pathway, as many as two thirds of the treatments that use this pathway would never reach patients, according to research released at the BIO International Convention last week.

69

69

pharmaphorum

JUNE 23, 2022

Novartis has shouldered its way into the in vivo gene editing category via a deal with US biotech Precision BioSciences, focused on a therapy for sickle cell disease (SCD). The Swiss pharma group is paying $75 million upfronting cash and equity to get the ball rolling on the collaboration, with another $1.4 billion in potential milestones if the project advances through development and onto the market.

97

97

Pharmaceutical Technology

JUNE 24, 2022

invoX Pharma has signed a definitive agreement for the acquisition of all issued and outstanding shares of clinical-stage biopharma firm F-star Therapeutics, in a deal valued at nearly $161m or $7.12 for each share in cash. invoX Pharma is a fully owned Sino Biopharmaceutical subsidiary. The latest deal will expedite the strategy of invoX to develop the International Biopharmaceutical R&D Platform of Sino Biopharm outside of China to transform the lives of patients globally.

Immunization 64

Immunization 64

Pharmacy Times

JUNE 23, 2022

But investigators find that individuals who had shingles that spread to the central nervous system had nearly twice the risk of developing mental deterioration, though it is rare.

139

139

Pharma Times

JUNE 21, 2022

Pre-clinical screening technology could increase cancer test numbers by 50 times

57

57